Company intelligence / Profile preview

DiNonA

Seoul, Seoul, Korea Republic of (South Korea)

Ownership: Private
Development stage: Commercial

Overview

DiNonA has developed monoclonal antibody-based therapeutics targeting cancer and immune-related indications. Its lead asset, leukotuximab targeting CD43 for leukemia, is in Phase 1. Other programs are in preclinical stages or discontinued. The company also markets over 30 rapid diagnostic tests covering infectious diseases, oncology markers, drug abuse detection, and pregnancy[2][3].

Therapeutic areas: OncologyInfectious DiseasesImmunologyPsychiatryWomen's Health
Modalities: Monoclonal antibodyDiagnostic reagent (for diagnostic products)
Industry: Biotech

Drug pipeline

2 assets

DNP007

1 more asset in the full pipeline.

Request access →

Partnerships

Samsung Biologics (manufacturing partnership for COVID19 monoclonal antibodies)

Beyond the preview

Go deeper on DiNonA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DiNonA.

Explore the full profile